Nocebo effects and participant information leaflets: evaluating information provided on adverse effects in UK clinical trials

por Kirby, Nigel, Shepherd, Victoria, Howick, Jeremey, Betteridge, Sophie, Hood, Kerenza
Publicado 2020

Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial

por Burnett, Alan K, Das Gupta, Emma, Knapper, Steve, Khwaja, Asim, Sweeney, Marion, Kjeldsen, Lars, Hawkins, Timothy, Betteridge, Sophie E, Cahalin, Paul, Clark, Richard E, Hills, Robert K, Russell, Nigel H
Publicado 2018

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial

por Othman, Jad, Wilhelm-Benartzi, Charlotte, Dillon, Richard, Knapper, Steve, Freeman, Sylvie D., Batten, Leona M., Canham, Joanna, Hinson, Emily L., Wych, Julie, Betteridge, Sophie, Villiers, William, Kleeman, Michelle, Gilkes, Amanda, Potter, Nicola, Overgaard, Ulrik Malthe, Mehta, Priyanka, Kottaridis, Panagiotis, Cavenagh, Jamie, Hemmaway, Claire, Arnold, Claire, Dennis, Mike, Russell, Nigel H.
Publicado 2023